New hope for lung scarring: buloxibutid trial underway
Disease control
Ongoing
This Phase 2 trial tests an oral drug called buloxibutid in 378 people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Over 52 weeks, researchers compare two doses of buloxibutid against a placebo to see if it can slow lung function decline. The study is double…
Phase: PHASE2 • Sponsor: Vicore Pharma AB • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC